# US 2026/0265746 A1 · Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265746 A1
- Document ID: US20260265746A1
- Status: Published application
- Kind: A1
- Application number: 19/411,463
- Filed: 2025-12-08
- Published: 2026-09-10
- Earliest claimed: 2011-06-21
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Brian Bettencourt; Kevin Fitzgerald; Stuart Milstein; Martin A. Maier; Klaus Charisse; Kallanthottathil G. Rajeev; Satyanarayana Kuchimanchi; Muthiah Manoharan; Tuyen M. Nguyen
- Web page: https://patentgrep.com/patent/US20260265746A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3521: Methyl
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

## Claims

### Claim 1

A double-stranded ribonucleic acid (dsRNA), or a salt thereof, for inhibiting expression of an APOC3 gene,
wherein the dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand and the antisense strand are each 30 nucleotides or less in length, and wherein the antisense strand comprises at least 15 contiguous nucleotides from any one of the antisense strand nucleotide sequences in any one of Tables 1, 2, 6, 7, and 10.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The dsRNA, or a salt thereof, of claim 1, wherein the nucleotide sequence of the sense strand is selected from any one of the sense strand nucleotide sequences in any one of Tables 1, 2, 6, 7, and 10, and the nucleotide sequence of the antisense strand is selected from any one of the antisense strand nucleotide sequences in any one of Tables 1, 2, 6, 7, and 10.

### Claim 4 (depends on 1)

The dsRNA, or a salt thereof, of claim 1, wherein at least one nucleotide of the dsRNA is a modified nucleotide.

### Claim 5 (depends on 4)

The dsRNA, or a salt thereof, of claim 4, wherein the modified nucleotide is selected from the group consisting of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

### Claim 6 (depends on 4)

The dsRNA, or a salt thereof, of claim 4, wherein the modified nucleotide is selected from the group consisting of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

### Claim 7 (depends on 1)

The dsRNA, or a salt thereof, of claim 1, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide or at least 2 nucleotides.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The dsRNA, or a salt thereof, of claim 1, further comprising a ligand.

### Claim 10 (depends on 9)

The dsRNA, or a salt thereof, of claim 9, wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA.

### Claim 11 (depends on 9)

The dsRNA, or a salt thereof, of claim 9, wherein the ligand is an N-Acetyl-Galactosamine derivative.

### Claim 12 (depends on 1)

An isolated cell comprising the dsRNA, or a salt thereof, of claim 1.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition for inhibiting expression of an APOC3 gene comprising the dsRNA, or a salt thereof, of claim 1.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, comprising a lipid formulation.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, comprising a lipid formulation comprising MC3.

### Claim 18 (depends on 1)

A method of inhibiting APOC3 expression in a cell, the method comprising:
(a) contacting the cell with the dsRNA, or a salt thereof, of claim 1; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an APOC3 gene, thereby inhibiting expression of the APOC3 gene in the cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein the APOC3 expression is inhibited by at least 30%.

### Claim 20 (depends on 1)

A method of treating a disorder mediated by APOC3 expression comprising administering to a human subject in need thereof a therapeutically effective amount of the dsRNA, or a salt thereof, of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the human subject has an elevated triglyceride level.

### Claim 22 (depends on 20)

The method of claim 20, wherein the human subject has a triglyceride level of >150 mg/dL or >500 mg/dL.

### Claim 23 (depends on 20)

The method of claim 20, wherein administration of the dsRNA, or a salt thereof, causes an increase in lipoprotein lipase and/or hepatic lipase activity.

### Claim 24

(canceled)

### Claim 25 (depends on 20)

The method of claim 20, wherein the disorder is hypertriglyceridemia.
